Eli Lilly, a renowned pharmaceutical company, has joined forces with the legendary basketball player Shaquille O'Neal to launch an innovative sleep apnea awareness campaign. This collaboration aims to shed light on the often-overlooked condition of obstructive sleep apnea (OSA), which affects a staggering 24 million adults in the United States. The campaign, titled 'Don't Sleep On OSA', is set to make a significant impact by utilizing O'Neal's influence and popularity.
In a recent announcement, Eli Lilly revealed that O'Neal will be the face of their campaign, directing attention to the dedicated website (https://dontsleeponosa.lilly.com/) through various digital and media platforms. This partnership is particularly meaningful as O'Neal himself was diagnosed with OSA over 15 years ago. He shares his personal experience, mentioning his constant fatigue, snoring, and nighttime struggles, which led him to seek medical advice. The campaign website offers valuable resources and information about OSA, including a helpful tool to book a sleep study through LillyDirect, their online pharmacy.
The campaign's highlight is a 30-second video featuring O'Neal, where he dispels the myth of his 'superhuman' status by openly discussing his OSA struggles. He humorously showcases everyday activities that OSA patients might find challenging, such as snoring, napping on the couch, and even opening a jar of pickles. O'Neal's message is clear: 'Talk to your doctor' and don't ignore the symptoms. This approach aims to encourage early diagnosis and treatment, breaking the stigma surrounding OSA.
Lina Polimeni, the consumer chief marketing officer at Eli Lilly, emphasized the significance of this collaboration, stating that O'Neal's authenticity, relatability, and cultural influence will help spark conversations about OSA. The campaign's goal is to empower individuals to recognize the symptoms and take proactive steps towards better health. This initiative is part of Lilly's broader efforts to address health equity and raise awareness about OSA, a condition often associated with obesity.
Eli Lilly's entry into the OSA therapy market was marked by the approval of Zepbound, a prescription medicine designed to treat adults with OSA and obesity. This development further solidifies Lilly's commitment to improving healthcare outcomes and addressing the needs of patients with OSA. With O'Neal's involvement, the campaign is poised to reach a wide audience, fostering a much-needed dialogue about sleep apnea and its impact on daily life.
